Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

Status unconfirmed · Not applicable · Has a placebo group

Conditions studied: Healthy

In brief

Glucagon has been used for decades as a test of growth hormone (GH) reserve. The pathway by which GH is stimulated by glucagon is not established. Acyl ghrelin has been shown to increase GH levels and to be stimulated by an increase in adrenergic activity. The proposed study will test the concept that with the fall in blood glucose it is likely that there is a sympathetic discharge which contributes to the increase in acyl ghrelin and indirectly leads to the increase in GH and cortisol.

Key facts

Study ID

NCT01795235

Run by

University of Virginia

People needed

6

Starts

2012-12-01

Expected to finish

2014-07-01

Last updated by the study team

2013-02-20

Who can join

Age: 18 and older, up to 30. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy normal men
• Age 18-30 yrs
• BMI 18-27 kg/m2

You may not qualify if…

• Medication or previous surgery known to affect ghrelin secretion.
• Medications known to have an impact on body weight (Seroquel, tricyclic antidepressants).
• Medications known to have an impact on the beta adrenergic system.
• Coronary artery disease, congestive heart failure, peripheral vascular disease, diabetes mellitus, significant hypertension (BP >180 systolic or >100 diastolic at rest); renal, hepatic, pulmonary disease; untreated hypothyroidism, untreated hyperthyroidism; history of seizure disorder; history of malignancy (other than some skin cancers), history of active chronic infections (e.g., HIV, tuberculosis).
• Endocrine disorders, i.e., pheochromocytoma, adrenal insufficiency
• Hematocrit < 41% men
• History of daily tobacco use within past 3 months
• Chronic alcohol abuse by history
• Weight not stable (more than 10% weight change or more over past 6 months)
• Strenuous exercise for average of more than 60 min/day
• Investigational drug within past 6 weeks
• Psychiatric history especially eating disorders
• Transmeridian travel within 2 weeks prior to or during study
• Known hypersensitivity to beta-blockers
• Estimated Glomerular Filtration Rate below 60 mL/min/1.73m2.
• Known cardiac dysrhythmia, especially first degree heart block. -

Where it is running

• University of Virginia — Charlottesville, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.